Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
caffeine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| TKI258 (dovitinib) | EXPERIMENTAL | dovitinib, 5 days on / 2 days off dose schedule |
| Name | Type | Description |
|---|---|---|
| caffeine | DRUG | single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam |
| diclofenac | DRUG | single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam |
| omeprazole | DRUG | single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam |
| midazolam | DRUG | single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam |
| TKI258 | DRUG | dovitinib, 5 days on / 2 days off dose schedule |
Inclusion Criteria: * Patients with a cytopathologically or histopathologically confirmed diagnosis of an advanced solid tumor, excluding breast cancer which has progressed despite standard therapy or for which no standard therapy exists * ECOG performance status 0 or 1 and anticipated life expecta...
Caffeine is an investigational small molecule being studied in advanced solid tumors, excluding breast cancer. It was evaluated in a Phase 1 pharmacokinetic drug-drug interaction study in patients with these tumors. The study has been completed, and caffeine remains in clinical development for this oncology indication.
Caffeine is being developed by Novartis AG, a pharmaceutical company traded on the New York Stock Exchange under the ticker NVS. The company sponsored a Phase 1 clinical trial of caffeine in patients with advanced solid tumors, excluding breast cancer.
Caffeine is in Phase 1 clinical development for advanced solid tumors, excluding breast cancer. It has completed one Phase 1 trial, which was a pharmacokinetic drug-drug interaction study. Caffeine is investigational and has not been approved for this indication.
Caffeine has been studied in one clinical trial, NCT01596647, titled 'Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors.' This Phase 1 study enrolled 39 patients in the United States and has been completed.
Caffeine is not the same as dovitinib. In the clinical trial NCT01596647, caffeine was studied in combination with dovitinib (TKI258) to assess a potential drug-drug interaction. Caffeine is a separate compound, and the trial evaluated how dovitinib affects caffeine's pharmacokinetics.